OLIVOTTO, IACOPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.851
EU - Europa 12.753
AS - Asia 2.974
AF - Africa 70
SA - Sud America 24
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 31.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.762
RU - Federazione Russa 4.510
PL - Polonia 3.659
IT - Italia 1.501
IE - Irlanda 1.277
SE - Svezia 923
SG - Singapore 876
CN - Cina 694
HK - Hong Kong 634
IN - India 265
JO - Giordania 221
GB - Regno Unito 189
DE - Germania 178
VN - Vietnam 169
FI - Finlandia 108
CA - Canada 88
CH - Svizzera 68
UA - Ucraina 68
ES - Italia 57
FR - Francia 53
CI - Costa d'Avorio 47
NL - Olanda 43
KR - Corea 28
JP - Giappone 27
BE - Belgio 24
DK - Danimarca 21
BR - Brasile 17
IR - Iran 15
LT - Lituania 13
RO - Romania 13
TR - Turchia 11
GR - Grecia 10
GH - Ghana 9
AT - Austria 8
PT - Portogallo 8
MY - Malesia 7
RS - Serbia 7
PH - Filippine 5
TW - Taiwan 5
AU - Australia 4
ID - Indonesia 4
NO - Norvegia 4
PK - Pakistan 4
EC - Ecuador 3
EU - Europa 3
IL - Israele 3
MA - Marocco 3
MU - Mauritius 3
PY - Paraguay 3
TN - Tunisia 3
BY - Bielorussia 2
HU - Ungheria 2
LY - Libia 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BG - Bulgaria 1
CL - Cile 1
CZ - Repubblica Ceca 1
GE - Georgia 1
HR - Croazia 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MT - Malta 1
PA - Panama 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 31.680
Salva come PNG Salva come JPEG
Città #
Santa Clara 4.996
Warsaw 3.644
Fairfield 1.601
Dublin 1.272
Ashburn 936
Woodbridge 776
Chandler 743
Singapore 733
Seattle 692
Cambridge 620
Houston 606
Wilmington 547
Lawrence 445
Altamura 435
Hong Kong 384
Florence 283
Moscow 276
Princeton 272
Ann Arbor 271
Boston 210
Mumbai 204
Beijing 195
Dong Ket 151
Shanghai 138
Buffalo 131
San Diego 128
New York 123
Medford 102
Munich 81
Boardman 79
Rome 59
Bern 56
Helsinki 56
Jacksonville 56
Norwalk 50
London 48
Abidjan 47
Milan 46
Toronto 43
Barcelona 42
Los Angeles 40
Falls Church 38
West Jordan 38
Yubileyny 35
Hillsboro 34
Ottawa 34
Naples 33
Kent 31
Andover 30
Guangzhou 30
Redwood City 24
Bologna 23
Brussels 23
Seoul 23
Phoenix 22
Nanjing 21
Washington 21
Scandicci 20
Copenhagen 19
Pune 19
Frankfurt am Main 17
Lappeenranta 17
Prato 17
Wuhan 17
Turin 14
Zhengzhou 14
Kilburn 13
Redmond 13
Shenzhen 12
Bengaluru 11
Siena 11
Council Bluffs 10
Romola 10
São Paulo 10
Dearborn 9
Palermo 9
Chennai 8
Laurel 8
Livorno 8
Pontedera 8
Salerno 8
Tehran 8
Birmingham 7
Changsha 7
Chicago 7
Genoa 7
Grottaglie 7
Kajang 7
Lecce 7
Paris 7
Timisoara 7
Campi Bisenzio 6
Falkenstein 6
Fontebuona 6
Hangzhou 6
Hefei 6
Wandsworth 6
Accra 5
Belgrade 5
Carmignano 5
Totale 22.501
Salva come PNG Salva come JPEG
Nome #
"Tuscany Registry for sAdden Cardiac DEath": metodo per la creazione di un registro multicentrico per la gestione di eventi di morte improvvisa in età giovanile 331
Atrial Remodeling in Hypertrophic Cardiomyopathy 283
Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: A comparison of the cardiac troponin T E163R and R92Q mouse models 268
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. 265
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. 259
Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. 254
Regulation of intracellular Na+ in health and disease: pathophysiological mechanisms and implications for treatment 246
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils 245
Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience 241
Late sodium current inhibitors to treat exercise induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. 217
β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy 202
Clinical profile and outcome of cardiac involvement in MELAS syndrome 199
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy 197
Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center 189
Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations 182
Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy 180
Accade-MIA. Territorio, Università e Ospedale si incontrano. Il racconto di un’esperienza 178
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy 177
Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care 176
IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE 169
The Missense E258K-MyBP-C Mutation Increases the Energy Cost of Tension Generation in Both Ventricular and Atrial Tissue from HCM Patients 168
Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil 167
Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study 166
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy 164
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy 164
Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC) 164
Life-Threatening Acute Pulmonary Thromboembolism Following Severe Carbon Monoxide Poisoning 163
Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: a Translational Study 162
Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude 160
Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy 158
Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment 157
Can anthropology improve our care of inherited cardiac arrhythmias? A modest proposal 152
An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy 150
Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy 147
Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy 147
Electrophysiological correlates of word recognition memory process in patients with ischemic left ventricular dysfunction 145
Malattia di Anderson-Fabry 145
Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy 145
Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: The case of hypertrophic cardiomyopathy 144
Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria 143
Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis 142
Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy 140
Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events 140
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. 139
Stress echo 2020: The international stress echo study in ischemic and non-ischemic heart disease 139
The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results 139
International external validation study of the 2014 European society of cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM) 138
Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy 137
Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy 137
Left Ventricular Apex Involvement in Hypertrophic Cardiomyopathy 136
Cardiac involvement in Churg Strauss syndrome: an update on cardiological manifestations 136
Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives 135
Late Sodium Current Inhibition Reverses Electro-Mechanical Dysfunction in Human Hypertrophic Cardiomyopathy 135
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe) 134
Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: A combined cardiopulmonary-echocardiographic study 134
Contemporary genetic testing in inherited cardiac disease: Tools, ethical issues, and clinical applications 133
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. 132
Beta-Blockers for Prevention of Exercise-induced Left Ventricular Outflow Obstruction in Patients with Hypertrophic Cardiomyopathy 132
Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation 131
Acceptability, Feasibility and Preliminary Evaluation of a Novel, Personalised, Home-Based Physical Activity Intervention for Chronic Heart Failure (Active-at-Home-HF): a Pilot Study 127
Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. 126
MR imaging in hypertrophic cardiomyopathy: From magnet to bedside 126
Heritability in genetic heart disease: The role of genetic background 125
Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing? 125
Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. 124
The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy 124
The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy 124
Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C 121
Abrupt onset of refractory heart failure associated with light-chain amyloidosis in hypertrophic cardiomyopathy 121
Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy 120
Novel α-Actinin 2 Variant Associated With Familial Hypertrophic Cardiomyopathy and Juvenile Atrial Arrhythmias: A Massively Parallel Sequencing Study. 120
European cardiomyopathy pilot registry: EURObservational research programme of the European society of cardiology 119
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy 118
Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation 118
The coronary circulation and blood flow in left ventricular hypertrophy 117
Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients with Hypertrophic Cardiomyopathy 117
Genetic tailoring of electrophysiological management in hypertrophic cardiomyopathy 117
Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates 116
Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders 115
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy 115
Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy 114
Response to Letter Regarding Article, "Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy" 114
Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy 113
Association of Obesity with Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy 113
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal 112
Genetic testing in pediatric cardiomyopathies: Implications for diagnosis and management 112
Patterns of Disease Progression in Hypertrophic Cardiomyopathy. An Individualized Approach to Clinical Staging 112
Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2 111
Performance of the CHA 2 DS 2 -VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia 111
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. 110
Is fast cross-bridge detachment a common feature to MYH7 and MYBP3 FHC-associated mutations in human cardiac myofibrils? 110
Grey zones in cardiomyopathies: Defining boundaries between genetic and iatrogenic disease 110
Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: A retrospective database analysis 110
Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study 110
Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial 110
Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®) 110
Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy 109
Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression 109
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study 109
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 109
Totale 14.911
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.934
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.934
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.642 0 0 0 0 0 462 756 774 641 381 510 118
2020/20214.142 319 447 184 558 218 330 248 354 372 686 172 254
2021/20222.144 106 83 188 83 46 119 91 130 252 135 319 592
2022/20235.281 456 1.217 302 176 288 903 736 286 571 54 173 119
2023/20242.747 111 224 369 140 164 417 156 543 89 268 146 120
2024/202512.225 630 1.837 1.020 2.560 4.383 1.795 0 0 0 0 0 0
Totale 32.167